NYSE:CRLLife Sciences
Charles River Labs Reshapes Gene Therapy Role While Legal Risks Linger
Charles River Laboratories International (NYSE:CRL) has entered a new gene therapy collaboration with Gazi University focused on a rare disease program.
The company has announced acquisitions of K.F. Cambodia and full ownership of PathoQuest SAS to expand its non human primate supply and sequencing capabilities.
A CEO transition is planned for May 2026, alongside ongoing DOJ related investigations and securities class action lawsuits tied to past disclosure issues.
For investors watching...